Which of the current available production techniques should be chosen for long, complex and functionalized peptides or even small proteins?

Which technologies allow functionalization of peptides?

Get answers to these questions by joining our next webinar where experts are discussing the pros and cons of today’s technologies for SPPS, native chemical ligation, CEPS, KAHA and recombinant technologies.

Submit your questions to our experts prior to the webinar via email (webinar@bachem.com).

Additionally, you can ask your questions either during the Q&A session of the webinar or in a discussion round afterwards (link to be provided during webinar).

Speakers:

Dr. Leendert Van Den Bos
CEO at EnzyTag BV

Dr. Leendert van den Bos obtained his MSc- and PhD-degree in bio-organic chemistry from Leiden University. In 2007, he joined Organon BioSciences as a Scientist and worked subsequently for Schering-Plough, Merck Sharp & Dohme and Aspen Pharmacare mostly in the field of Process Research & Development. In 2018 he co-founded EnzyTag focusing on the development of chemo-enzymatic processes for complex peptide API’s. Leendert holds an Executive MBA from Nyenrode University.

Dr. Anna Koijen
Senior Scientist at EnzyTag BV

Anna Koijen studied biotechnology at FH Aachen, University of Applied Sciences, and the University of Münster. Afterwards she pursued a PhD at Forschungszentrum Jülich, during which she focused on enzyme engineering for the stereoselective formation of chiral building blocks. In 2019 Anna joined EnzyTag as a scientist working on the chemo-enzymatic synthesis of peptides and proteins using the peptiligase technology.

Dr. Bernd Raschack
Senior Business Development Manager

Bernd Raschack studied chemistry and received his diploma at the Albert-Ludwigs University in Freiburg, Germany. He earned his doctorate from the same University in close cooperation with pharmaceutical company Knoll AG (now Abbvie) in Ludwigshafen, Germany. His dissertation was about studying the influence of the Growth Arrest Homeobox Gene (GAX) on the process of restenosis and its suitability as a potential gene therapeutic target.

Bernd joined Bachem AG in Bubendorf, Switzerland in 2001. He was the first hired staff with the aim to establish a sustainable NCE (New Chemical Entity) customer pipeline for Bachem in Europe. He also earned a diploma from Fachhochschule Nordwestschweiz (FHNW) in 2005 about his work on analyzing and suggestions for improving Key Account and Project Management aspects at Bachem. He served in different functions with increasing responsibilities as Key Account Manager, Business Development Manager, Group Leader Business Development and Senior Business Development Manager.